Genetic investigation of four meiotic genes in women with premature ovarian failure

Béatrice Mandon-Pépin, Philippe Touraine1, Frédérique Kuttenn1, Céline Derbois2, Agnes Rouxel1, Fumihiko Matsuda2, Alain Nicolas3, Corinne Cotinot and Marc Fellous4

INRA, UMR 1198, ENVA, CNRS, FRE 2857, Biologie du Développement et Reproduction, Jouy-en-Josas F-78350, France, 1APHP, Department of Endocrinology and Reproductive Medicine, GH Pitie Salpétreire, 47-83 Bd de l’Hôpital, 75651 Paris Cedex 13, France, 2Centre National de Génotypage, 2 rue Gaston Crémieux, 91057 Evry, Cedex, France, 3CNRS, UMR144, Génétique Moléculaire de la Recombinaison, Institut Curie, 26 rue d’Ulm, 75248 Paris Cedex 05, France and 4INSERM, U709, Genomics and Epigenetics of Placentary Pathology, Hôpital Cochin, 123 Bd de Port Royal, 75014 Paris, France

(Correspondence should be addressed to B Mandon-Pépin; Email: beatrice.pepin@jouy.inra.fr)

Abstract

Objective: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).

Design: Case–control study.

Methods: Blood sampling, karyotype, hormonal dosage, ultrasound, and ovarian biopsy were carried out on most patients. However, the main outcome measure was the sequencing of genomic DNA from peripheral blood samples of 41 women with POF and 36 fertile women (controls).

Results: A single heterozygous missense mutation, substitution of a cytosine residue with thymidine in exon 2 of MSH5, was found in two Caucasian women in whom POF developed at 18 and 36 years of age. This mutation resulted in replacement of a non-polar amino acid (proline) with a polar amino acid (serine) at position 29 (P29S). Neither 36 control women nor 39 other patients with POF possessed this genetic perturbation. Another POF patient of African origin showed a homozygous nucleotide change in the tenth of DMC1 gene that led to an alteration of the amino acid composition of the protein (M200V).

Conclusions: The symptoms of infertility observed in the DMC1 homozygote mutation carrier and in both patients with a heterozygous substitution in exon 2 of the MSH5 gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function. MSH5 and DMC1 mutations may be one explanation for POF, albeit uncommon.

Introduction

Premature ovarian failure (POF; OMIM no. 311360) is a cause of female infertility due to the loss of normal ovarian function in women before the age of 40 years (1). The condition is defined by the absence or cessation of normal menses for at least 6 months (primary or secondary amenorrhea), menopausal level of follicle-stimulating hormone (FSH) >40 mIU/ml, hypoestrogenism and infertility (2, 3). POF affects 1 and 0.1% of women by 40 and 30 years of age respectively. POF is not uncommon considering the incidence rate of 1–2% of women during their reproductive life.

Several mechanisms may be involved in POF pathogenesis such as viral or autoimmune inflammatory disease, environmental toxics, and radiation or chemotherapy, but the genetic contribution is a significant etiological component. However, the disorder can occur on a familial basis, and there is evidence for a genetic mechanism in at least some cases. Deletions and translocations involving three regions of the X chromosome (Xq13-22, Xq26-28, and Xp11.2-22.1) have been associated with POF (4–9). Several genes located on this chromosome (i.e., bone morphogenetic protein-15 BMP15, kit ligand KITLG) have been sequenced in cohorts of POF patients, and heterozygous variants were detected but their frequency remained rare and did not appear to be a common cause of POF (10–13).

Candidate gene approaches have revealed few mutations in the gonadotropins and their receptors (14, 15) except noteworthy missense variant Ala189 Val of the FSH receptor gene which was strongly associated with POF in the Finnish population but rare in other world populations (16–19). POF can also be associated in familial syndromes such as type 1 blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES; OMIM no. 110100) (20). Several FOXL2 gene mutations have been reported in the type 1 BPES and nonsyndromic POF cases but are uncommon in diverse
populations (21, 22). Recently, attention has been focused on members of the transforming growth factor-β (TGF-β) superfamily synthesized by the oocyte, growth differentiation factor-9, and BMP15. These studies identified several heterozygous variants that are significantly more prevalent among women with POI but they are not a major cause of ovarian insufficiency (13, 23–25).

Mutations in autosomal genes (galactose-1-phosphate uridylyltransferase, GALT; transforming growth factor beta receptor, TGFBR3; inhibin alpha, INHA; forkhead box E1, FOXE1; and β-glycerophosphate dehydrogenase, MSH5) have also been related to POI (23, 24, 26–30). Nevertheless, in most cases, the etiology of the disease remains unknown.

In the ovary, primordial germ cells enter into meiosis from week 9 post-conception, oocytes pass through leptotene, zygotene, and pachytene stages before arresting in the last stage of meiotic prophase I, the diplotene, or dictyate stage at about the time of birth. It is widely accepted, although recently debated, that in mammals a female is born with a fixed number of oocytes within the ovaries (31, 32). The fertile lifespan of a female depends on the size of the oocyte pool at birth and the rapidity of the oocyte pool depletion. The phenotype of ovaries in null mutant mice for several meiotic genes could be strikingly similar to clinical observations found in human infertility and POI. In female mice lacking the Dmc1 gene, normal oogenesis was aborted in embryos, and germ cells disappeared in the adult ovary (33, 34). The ovaries of Msh5−/− female mice are normal in size at birth, but degenerate progressively to become rudimentary, concomitant with the decline in oocyte numbers from day 3 pp until adulthood (35). The aim of this study was to screen a cohort of 41 clinically well-characterized patients who present unexplained infertility (normal XX karyotype, women with POI) for mutations in four meiotic genes. For this purpose, the exons of these four genes (DMC1, SPO11, MSH4, and MSH5) were sequenced and compared with the human corresponding gene to evaluate the impact of meiotic prophase arrest in 46 XX females with ovarian disorders.

**Materials and methods**

**Patients and control population**

Patients (n = 41) were mainly (n = 35) recruited from the reproductive endocrine unit of Pitie-Salpetriere Hospital, Paris, France. The diagnostic criteria for POI include at least 6 months of amenorrhea before the age of 40 years, with high serum FSH levels (> 40 IU/l). In two cases, however, patients were included without fulfilling these criteria. The first one had an FSH level of 38 mUI/l but with a familial history of POI. The second patient had clinical symptoms suggesting Turner’s syndrome (short size, bradymetacarpia, and multiple nevi) but with a normal karyotype. However, hypoestrogenism was associated with mild increase of FSH level (18 mUI/l). Since a mutation of one of the studied meiotic genes has been identified in this patient, we considered it necessary to still maintain the patient in our cohort. Karyotyping with a high-resolution G-banding was carried out for all the patients. This study was approved by the institutional review board of the hospitals, and all participants gave their written informed consent. The control population provided by the Centre National of Genotypage (CNG) included 36 Caucasian women having at least one child and no history of infertility. A second group of control population originating from Senegal (n = 32) was also tested for the tenth exon of DMC1 gene.

**DNA extraction and PCR**

Genomic DNA was isolated from peripheral blood samples using the standard phenol–chloroform procedure. The DMC1, MSH4, MSH5, and SPO11 genes are composed of 14, 20, 25, and 13 exons respectively. The sequencing project was performed at the CNG (Evry). All primers were designed using the software Primer 3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3www.cgi). The first PCR amplification, using intronic oligonucleotide primers flanking the exons, was performed in a 15 µl volume containing 25 ng genomic DNA, 2.5 pM of each primer, and 0.75 U Taq polymerase (ExTaq, Takara, Camburg, MD, USA). After an initial denaturation step at 94 °C for 5 min, 34 cycles of amplification were performed consisting of 5 s at 98 °C, 30 s at 60 °C, a 30 s elongation step at 72 °C, and one 10 min terminal elongation step. Primer sequences of DMC1 and MSH5 genes are given in Tables 1 and 2.

**DNA sequencing and in silico analysis**

All the PCR products containing the exons and flanking regions of each gene were purified using BioGel P-100 (Bio-Rad laboratories). To 2 µl sense or antisense sequencing primer (1.5 µM) and 3 µl Bigdy terminator mix (Applied Biosystems, Foster City, CA, USA), 1 µl purified PCR products was added. The amplification consisted of an initial 5 min denaturation step at 96 °C, 25 cycles of 10 s of denaturation at 96 °C, and a 4 min annealing/extension step at 60 °C. The purified reaction products (G50 Sephadex spin column, Boehringer Mannheim) were sequenced on an ABI PRISM 3700 DNA Analyzer (Applied Biosystems).

Both strands from all patients and controls were sequenced for the entire coding region and the exon/intron boundaries. Alignment and single nucleotide polymorphism (SNP) analysis were performed with Genalys software developed by the CNG (37).

The sequence of each variant was confirmed by a new round of PCR amplification and sequencing. The potential deleterious effect of the amino acid
Changes was determined using PolyPhen software (http://tux.embl-heidelberg.de/ramensky/index.shtml). The multiple protein sequence alignment was realized with BioEdit and ClustalW (http://www.mbio.ncsu.edu/BioEdit/bioedit.html).

Results

Sequence analysis

The analysis of the coding sequence of DMC1 revealed a homozygous substitution in the tenth exon of one case (patient A), g.33551A>G (with respect to the sequence AY520538 in Genbank; Fig. 1). This leads to the change in amino acid M200V. The patient A was of African origin (from Senegal, Sarakholé ethnic group). In order to determine the frequency of this genetic perturbation in a control population originating from Senegal, 32 additional DNA samples provided by Pasteur Institute (Dakar) were tested for exon 10. All individuals originated from the same geographic region and ethnic group (Sarakholé) as the patient’s family.

Two DNA controls presented a heterozygous transition g.2547C>T (with respect to the sequence AY943816 in Genbank) that altered codon 29 of the protein resulting in a proline-to-serine change (P29S). This mutation leads to the change from a medium size hydrophobic amino acid (P) to a small polar amino acid (S), and this variant is predicted to be possibly damaging by the Polyphen program prediction (PSIC score difference = 1.800).

This variant was present in two POF patients (patients B and C). It was not found in any control (n = 36). The sequencing of one patient’s family (patient B) revealed the presence of the variant in the DNA of the father and the young sister (Fig. 2B).

The sequencing of MSH4 and SPO11 genes revealed no intragenic mutation. We detected only several SNPs present in similar frequency in patients and controls (data not shown).

Patient’s phenotype

The mean patient age was 26.5 (15–39) years. The patients presented with the following clinical patterns: primary amenorrhea with absence of or interrupted puberty (n = 6) and secondary amenorrhea with normal puberty (n = 23). Eleven patients had a familial history of POF. Mean FSH level was 73.2 mUI/l (18–141).

DMC1-M200V

Patient A was a 28-year-old African woman. Puberty occurred normally when she was 15, with regular

www.eje-online.org

Table 1 Sequences of PCR and sequencing primers for the human DMC1 gene.

<table>
<thead>
<tr>
<th>DMC1 gene</th>
<th>PCR primers</th>
<th>Sequencing primers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exon 1</td>
<td>5'TCCAGGTTCAAGCGAT-3'</td>
<td>5'TCAGGCACATCTGTGTCATGT-3'</td>
</tr>
<tr>
<td>Exon 2</td>
<td>5'GCATACACATCTTGGAG-3'</td>
<td>5'TGAGCTAGCTCTTACCTAC-3'</td>
</tr>
<tr>
<td>Exon 3</td>
<td>5'CTGTGGCTAGTTGGGAGTACG-3'</td>
<td>5'GTTGTTGGGAAAGGAGTACG-3'</td>
</tr>
<tr>
<td>Exon 4</td>
<td>5'ACACAGCTAGACTCCATCTC-3'</td>
<td>5'ACATATGGAAGAGTGAAC-3'</td>
</tr>
<tr>
<td>Exon 5</td>
<td>5'CAGCTCACCGCTCCTCCTACTA-3'</td>
<td>5'GGCATGTTACCTGGCTCCTGCA-3'</td>
</tr>
<tr>
<td>Exon 6</td>
<td>5'TATTTTGCTCTGCTCCTCATGAG-3'</td>
<td>5'GTCCTCCTGACTCGTATACATG-3'</td>
</tr>
<tr>
<td>Exon 7</td>
<td>5'AGCTCTGCTCTGACTCCATCTC-3'</td>
<td>5'AGGCTGCTCCTGACTCCATCTC-3'</td>
</tr>
<tr>
<td>Exon 8</td>
<td>5'GAGTTGAGGGAAGGTTCCCTGGA-3'</td>
<td>5'GACAGTCTAGCTAGCTAACC-3'</td>
</tr>
<tr>
<td>Exons 9+10</td>
<td>5'CCAGCTCTGAGGTCTGTGCTAG-3'</td>
<td>5'CCAGCTCTGAGGTCTGTGCTAG-3'</td>
</tr>
<tr>
<td>Exon 11</td>
<td>5'AGACTCTGGCTGACTCCCTGAG-3'</td>
<td>5'AGACTCTGGCTGACTCCCTGAG-3'</td>
</tr>
<tr>
<td>Exon 12</td>
<td>5'GGCATGTTACCTGGCTCCTGCA-3'</td>
<td>5'GGCATGTTACCTGGCTCCTGCA-3'</td>
</tr>
<tr>
<td>Exon 13</td>
<td>5'GCAAGCAGCTAGACTCCCTGAG-3'</td>
<td>5'GCAAGCAGCTAGACTCCCTGAG-3'</td>
</tr>
<tr>
<td>Exon 14</td>
<td>5'GAGTTGAGGGAAGGTTCCCTGGA-3'</td>
<td>5'GAGTTGAGGGAAGGTTCCCTGGA-3'</td>
</tr>
</tbody>
</table>
menstrual cycles up to 21 years. A secondary amenorrhea occurred definitely since then. She was referred to our department when she was 28. POF was confirmed with a high FSH level (91 mUI/l); estradiol and inhibin B levels were low (<10 pg/ml and 15 ng/ml respectively). No anti-ovarian antibodies were found positive. Pelvic ultrasonography showed a small uterus (50 mm in its maximal length) and small-sized ovaries; no follicle was observed. An ovarian biopsy was performed confirming the follicular depletion. Familial study identified one sister with a spontaneous abortion.

**Table 2** Sequences of PCR and sequencing primers for the human MutS homolog 5 (MSH5) gene.

<table>
<thead>
<tr>
<th><strong>MSH5 gene</strong></th>
<th><strong>PCR primers</strong></th>
<th><strong>Sequencing primers</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Exon 1</td>
<td>Sense: 5'-ATGTCGCCAGTAGGGGTGT-3'</td>
<td>5'-AATCAGCCGTCAGACTCTTC-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-TGTCGCCCACTAGGGAGTGA-3'</td>
<td>5'-AGATTGTTGGAGAAACTCCAGC-3'</td>
</tr>
<tr>
<td>Exon 2</td>
<td>Sense: 5'-ATGAGGCTGGGCGGC-3'</td>
<td>5'-CCTCTGGTGAATCTGGTTCTC-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-TAGGGCATCAGGTACCCCC-3'</td>
<td>5'-GGCTCCAAAACCGTCTTTAT-3'</td>
</tr>
<tr>
<td>Exon 3</td>
<td>Sense: 5'-AGATTGGTCCTCACTGCCTTC-3'</td>
<td>5'-CTAAATGGGGGTAGTAGATGC-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-GTTGAGCTAGGAGGAATTC-3'</td>
<td>5'-GAGGAAATTCTAGGTCTCCATC-3'</td>
</tr>
<tr>
<td>Exons 4–5</td>
<td>Sense: 5'-GAATCTGGCATACAGGCTTC-3'</td>
<td>5'-GGGAGTGTTGTGTCTCTTCTC-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-CTGAGGCAGTGGCTTTCATG-3'</td>
<td>5'-GGAACAGGAGTTAGGCTAA-3'</td>
</tr>
<tr>
<td>Exons 6–8</td>
<td>Sense: 5'-ACTGCTCTAGTGACCTT-3'</td>
<td>5'-TACAAACCGGTTCCTCTGGC-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-CCCTCTCTCCTTCCTCTCA-3'</td>
<td>5'-AGGCCCCAGGAGTTAAGA-3'</td>
</tr>
<tr>
<td>Exon 9</td>
<td>Sense: 5'-GTTACCCCAACCGCCTACAGGA-3'</td>
<td>5'-AAAGCGATGTAATCTGAGA-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-ACAAGGCTCTCCCAAAGTCCC-3'</td>
<td>5'-GGAGGCAATTGCTTTGTCG-3'</td>
</tr>
<tr>
<td>Exon 10</td>
<td>Sense: 5'-CCTGTGAGTGTCCTACCTCC-3'</td>
<td>5'-AGCTCTCTCAAAACACAGCA-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-AATCCAAGGCTTCAGGCTTG-3'</td>
<td>5'-GAATAGTCCAGAGACTGTC-3'</td>
</tr>
<tr>
<td>Exons 11–12</td>
<td>Sense: 5'-CTCTGAAGGTAAGCTGGATG-3'</td>
<td>5'-GTAACTCTGGATAGCCCGAC-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-GTCTTGAACATGCTAGGGTG-3'</td>
<td>5'-GGCGTTAACCCTGGACTTTG-3'</td>
</tr>
<tr>
<td>Exons 13–14</td>
<td>Sense: 5'-TCTGTCTCTTCTCTAGACTG-3'</td>
<td>5'-CTGGATCTCTTCTCTGTGG-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-GACCACCTGCGCAAGGTAG-3'</td>
<td>5'-TGGCCAGGATGCTACTCAT-3'</td>
</tr>
<tr>
<td>Exons 15–18</td>
<td>Sense: 5'-CGCACTGAGAGAGACTCAT-3'</td>
<td>5'-AGGCCCGAGGAGACTCTTTT-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-TTGCGGCCCTTCTCATGCTA-3'</td>
<td>5'-AAGGTCACACGTCTTATGAA-3'</td>
</tr>
<tr>
<td>Exons 19–21</td>
<td>Sense: 5'-TAGACATGAGGGGGCCA-3'</td>
<td>5'-CTGGGGGGCTACTCCTTCTTG-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-CATATGCCCTTCTGCACCT-3'</td>
<td>5'-GTCCTGGTTCAGCTCTTCAT-3'</td>
</tr>
<tr>
<td>Exons 22–25</td>
<td>Sense: 5'-GCTGTTGTGGCGACAGAAAGAA-3'</td>
<td>5'-ATGCTAAACTCTGCTGGCCT-3'</td>
</tr>
<tr>
<td></td>
<td>Antisense: 5'-TACCTGACAGGAGGAGGT-3'</td>
<td>5'-GTTGTTGACAGGGTATGAC-3'</td>
</tr>
</tbody>
</table>

**MSH5-P29S**

The first heterozygous patient (patient B) was a Caucasian woman who was 18 years old when she was referred to our department. She first had menstruations when she was 14 with a normal puberty. However, an oligomenorrhea and a secondary amenorrhea appeared progressively. Clinically, she was short (1.46 m) and associated with an obesity (BMI: 32); had rough face, bradymetacarpia, and a mild intellectual deficiency. Hormonal evaluation identified a mild increase of FSH level (18 mUI/l); inhibin B was low (12 pg/ml). Ten days of progesterin treatment induced vaginal bleeding. Ultrasonography identified two ovaries that are small in size with multiple follicles depicted. Turner’s syndrome was suggested but high-resolution karyotype was found normal and repeated twice. Since the syndrome appeared uncommon, an ovarian biopsy was performed, identifying multiple primary follicles; a secondary follicle was also observed.

The second heterozygous patient (patient C) was also a Caucasian woman who was 36 years old when she was referred to our department. She had her first menstruations, associated with a normal pubertal development, when she was 13. She had oligomenorrhea between 13 and 18 years of age and then used oral contraceptive pills until she was 30. She became pregnant 6 months later and gave birth to a normal boy. She had menstruations following this but a secondary amenorrhea occurred definitely since then. She was referred to our department when she was 28. POF was confirmed with a high FSH level (71 mUI/l). Pelvic ultrasonography identified two ovaries that are small in size without follicles. Ten days of progestin treatment induced vaginal bleeding. Ultrasonography identified two ovaries that are small in size with multiple follicles depicted. Turner’s syndrome was suggested but high-resolution karyotype was found normal and repeated twice. Since the syndrome appeared uncommon, an ovarian biopsy was performed, identifying multiple primary follicles; a secondary follicle was also observed.
Discussion

The POF syndrome is a very heterogeneous clinical disorder probably due to the complex genetic networks controlling human oogenesis and folliculogenesis. It is often associated with small pedigrees that make it difficult to perform genetic linkage analysis to identify responsible genes. An alternative approach is to test candidate genes on the basis of existing knowledge of ovarian physiology.

Several meiotic genes known in yeast have been isolated in mammals, including Dmc1, Msh4, Msh5, and Spo11 genes (38–41).

Dmc1 is important for meiotic recombination in many organisms; for example, mice with targeted mutations of the Dmc1 gene are sterile and show hallmarks of poorly repaired DNA double-strand breaks. At birth, the mutant ovaries formed in Dmc1−/− mice contained a high proportion of oocytes whose nuclear features were characteristic of leptonema or zygonema, in contrast to the littermates, in which the majority of oocytes had progressed to the pachytene stage. Histological analysis showed that the adult ovaries from Dmc1−/− deficient mice contained no follicle at any developmental stage (33, 34). These results indicate that while germ cells are indeed formed in Dmc1−/− ovaries, the meiotic progression is blocked leading to progressive death of oocytes and subsequent complete depletion in the ovary by adulthood. The description of our clinical case is perfectly compatible with the animal model. Patient A had a normal gonadal function during a few years, which disappeared when she was 21. Since then, ovarian description, either by ultrasonography or histology, showed a complete absence of follicular reserve and/or maturation.

Msh5 is a member of a family of proteins known to be involved in DNA mismatch repair (42). Msh5−/− mice are viable but sterile (35). Meiosis in these mice is affected due to the disruption of chromosome pairing in prophase I. The ovaries of Msh5−/− females are normal in size at birth, but degenerate progressively to become rudimentary (35). The phenotype of Msh5−/− females differs from Dmc1−/− mice, in that the few oocytes remaining at 4–5 day pp in Msh5−/− ovaries are normal in appearance and have formed follicles (43). In contrast, ovaries from Dmc1 knockout females were very small and contained no follicle at any developmental stages. A less severe...
phenotype for Msh5 versus Dmc1 mutation has also been observed in yeast and worms (44, 45). This type of phenotype is in accordance with those observed in POF patients with a progressive loss of activity of the ovary leading to gonads reduced in size without germ cells; the oocytes having failed to progress to the dictyate stage in utero and subsequently degraded.

Nevertheless, the MSH5 protein of the POF patients is probably not completely defective and phenotypes could be less severe than those observed in null mice. However, in our patients, only heterozygous MSH5 mutation was described. The interspecific genotype difference (heterozygous in humans and homozygous in mice) could be explained by a more dosage-sensitive system in humans.

In both cases with MSH5 alteration, gonadal function appeared normal with a progressive involution. The most surprising data concern the youngest woman who presented with syndromic features. However, similarities in the ovarian phenotype in female Msh5+/− mice and Turner’s syndrome patients have been reported (35). It is also probable that this young woman will present with a complete POF in the near future. Indeed, the variability observed in clinical phenotypes (complete or partial infertility) could result from the age that the patients consult with clinicians. The sequencing of MSH5 gene in the family of this patient revealed that her 20-year-old young sister was also a carrier of the same variant. Until now, she had normal menses but she could be considered as a carrier of a genetic predisposition to develop POF in the future.

The resulting P29S alteration within MSH5 protein is located within the N-terminal region and it is conceivable that this amino acid change could directly impact the integrity of the protein interaction between MSH5 and MSH4. Amino acid sequence analysis revealed that the MSH5 N-terminal region contains a contiguous (Px)5 dipeptide repeat flanked by two PxxP motifs (46). This dipeptide repeat is disrupted in the MSH5 P29S variant. Moreover, this same mutation has previously been described in genomic DNA of patients with ovarian carcinoma (47). To address the effect of P29S alteration on the interaction between MSH4 and MSH5, a quantitative two-hybrid analysis has been performed. This alteration causes moderate but significant reduction between both proteins and could affect the formation of MSH4–MSH5 heterocomplex (47). The functionality of both proteins in meiotic homologous recombination process probably needs a precise interaction between them and any deviation from this precise coordination will be expected to affect the accuracy of DNA recombination. It is noteworthy that this alteration was found in two patient populations with ovarian pathology; the previous with ovarian cancer and the present with POF. These two pathologies could affect the capacity of DNA repair leading to either a progressive loss of germ cells or cancer formation. For this reason, it will be crucial to follow the degeneration of the ovary from our two patients on a long-term period to prevent an eventual ovarian carcinoma.

In summary, one homozygous missense mutation in DMC1 gene and one heterozygous in MSH5 were described here, in 3 of 41 POF patients. The DMC1 M200V mutation seems to generate a deleterious effect only in homozygous states since the mother and the

**Table 3** Major characteristics of the patients with mutation in meiotic genes.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Origin</th>
<th>FSH levels (mUI/l)</th>
<th>Follicle</th>
<th>Mutated gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>28</td>
<td>African</td>
<td>91</td>
<td>None</td>
<td>DMC1: g.33551A &gt; G Homozygous mutation</td>
</tr>
<tr>
<td>B</td>
<td>18</td>
<td>Caucasian</td>
<td>18</td>
<td>Multiple primary, 1 secondary</td>
<td>MSH5: g.2547C &gt; T Heterozygous mutation</td>
</tr>
<tr>
<td>C</td>
<td>36</td>
<td>Caucasian</td>
<td>71</td>
<td>None</td>
<td>MSH5: g.2547C &gt; T Heterozygous mutation</td>
</tr>
</tbody>
</table>
sister of this patient, carriers of the same mutation with heterozygous status are fertile. A multiple sequence alignment showed that the amino acid M200V was highly conserved across vertebrates, from chicken to primates (Fig. 3), suggesting a functional or structural role. Accordingly, Polyphen program prediction suggested a potential damaging effect of this mutation. The encoded substitution of a methionine for a valine at this residue is non-conservative in nature and affects a Dmc1 protein region which has been shown to facilitate binding. In addition, preliminary results on yeast have shown that the DMC1 M200V mutation of the conserved residue when introduced into *Schizosaccharomyces pombe* causes a significant decrease in meiotic recombination frequencies (work in progress).

However, further investigations will be needed to confirm the pathological role of these mutations such as screening of increased numbers of patients, and controls and generation of in vivo models using knock-in alleles in which missense mutations are introduced that mimic the kinds of mutations found in POF patients.

**Acknowledgements**

The authors thank Jeremy Don, MD, François Morel MD, Gilbert Schaison MD, and Joelle Belaish MD for their contributions to the collection of patient samples. We also extend thanks to Jerome Dulong and Alexandra Cibot for their technical assistance. We are also grateful to Pr. Dieye, Pasteur Institute from Dakar-Senegal for providing control DNA samples. Supported by an INSERM grant (GIS Maladies Rares AO2212KS).

**References**


38 Carson SA. Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertility and Sterility 2005 84 253–257.


41 Habu T, Taki T, West A, Nishikawa Y & Morita T. The mouse and human homologs of DMC1, the yeast meiosis-specific


45 Kelly KO, Dernburg AF, Stanfield GM & Villeneuve AM. *Caenorhabditis elegans* msh-5 is required for both normal and radiation-induced meiotic crossing over but not for completion of meiosis. *Genetics* 2000 156 617–630.


Received 3 September 2007
Accepted 7 October 2007